Annals of Neurology and Neuroscience
Review Article

Exploring the Intriguing World of "Dopamine" in Health and Disease: An Integrated Scientific Review

Abdulhakeem Jimoh, MD, MPH

Biology Department, Medgar Evers College of the City University of New York

Citation: *Abdulhakeem Jimoh. Exploring the Intriguing World of "Dopamine" in Health and Disease: An Integrated Scientific Review. Anna Neur & Neurosci. 2026;1(2):1-5.*

Received Date: 15 July, 2026; **Accepted Date:** 17 July, 2026; **Published Date:** 18 July, 2026

***Corresponding author:** Abdulhakeem Jimoh, MD, MPH. Biology Department, Medgar Evers College of the City University of New York

ABSTRACT

Dopamine is a vital chemical that can act as a neurotransmitter in the nervous system and as a neurohormone peripherally, with distinctive physiological effects that may influence optimal bodily functions.[1] Deficits or sub-optimal levels of dopamine pose a major physiological challenge, while its overproduction and hyperactivity may present with compromised specific neurologic or psychiatric manifestations. Dopamine is not only found in humans; there is documented evidence of its role in ameliorating adverse environmental conditions in plants.[2] There are integrated and interconnected neural pathways in the Brain that process and release dopamine, exerting significant effects across motivation, pleasure, reward, motor functions, and neuroendocrine control. Critically understanding these pathways, interactions, and neural elements of the associated brain regions provides an ideal framework for dissecting normal functioning and potential malfunction. It is important to emphasize that the clinical ramifications of dopaminergic pathways and their responses span neuroanatomy, neurophysiology, pathology, pharmacology, psychiatry, and clinical psychology. The objective of this review is to provide a concise integration of dopaminergic activities and relevant clinical entities for professionals with scientific and clinical orientations.

Keywords: Dopaminergic pathways; Dopamine; Neurotransmitter; Reward; Motor functions; Pathology; Neuroendocrine

INTRODUCTION

Dopamine is synthesized from the amino acid tyrosine, which is converted to L Dopa by tyrosine hydroxylase. L-DOPA is subsequently converted to Dopamine by DOPA decarboxylase, with tyrosine hydroxylase serving as the rate-limiting enzyme. This pathway supports both dopamine production in the nervous system and peripheral dopamine production, which is limited in its ability to cross the blood-brain barrier.[3] Their effects are exerted by interacting with dopamine receptors D1 and D2. D1 and D1 like receptors (D1& D5), which are generally located in the striatum, cerebral cortex, and hippocampus, when activated, result in an excitatory response ranging from impulse control, working memory, and attention. D2 and D2-like receptors (D2, D3, D4), on the other hand, are largely found in the limbic system, and the basal ganglia are inhibitory in nature, functioning to

control voluntary motor functions and emotional expressions.[4] Activation or blockage of these receptors is critical to the pathogenesis and manifestations of certain neurological lesions and to the effects of pharmacological agents. The full extent of dopaminergic activities can be examined through the mesolimbic, nigrostriatal, meso-cortical, and tuberoinfundibular pathways, which are the intervening pathways that modulate dopaminergic functions in the central nervous system and closely related disorders.[5]

DISCUSSION

The mesolimbic pathway projects from the ventral tegmental area of the midbrain, VTA, to the Nucleus accumbens (NAc), which operates as the brain reward center. The activities in this center underline the mechanism of addiction through motivation and pleasure-seeking behavior due to dopamine release. This pathway is hijacked by events such as drugs, alcohol, and gambling, which overstimulate dopamine production exponentially, and additional input from the prefrontal cortex, which motivates learning and reinforces repetition and subsequent dependence. Chronic drug and compulsive drug-seeking behavior may result from the gradual neuroadaptive changes in the mesolimbic dopaminergic transmission.[6] Understanding this pathology is critical to treatment and recovery efforts in the form of abstinence, as it starves the pathway of the expected flood of dopamine.

Lastly, hyperactivity in this region may increase presentations such as hallucinations, delusions, and paranoia, which are representative of the positive symptoms of schizophrenia.[7] This condition may be treated by antipsychotic medications, which block D2 receptors. Typical antipsychotics such as Chlorpromazine (Thorazine) and haloperidol (Haldol) are excellent agents with such pharmacological actions.[5]

The mesocortical dopaminergic pathway connects the ventral tegmental area (VTA) of the midbrain to the prefrontal cortex. The control of executive function and attention, decision-making, working memory, and emotions is characteristic of this pathway. Sub-optimal level dopaminergic activities may present in individuals with negative symptoms of schizophrenia, such as flat affect and anhedonia.[8]

Additionally, Attention deficit hyperactivity disorder, ADHD, a disorder characterized by inattentiveness, poor working memory, and impulse control disruption, may result from a low level of dopamine, which compromises the effectiveness of the pre-frontal cortex in exerting its executive regulatory function. The most notable findings in ADHD are a generalized reduction in brain size, particularly in the caudate nucleus, the white matter of the prefrontal cortex, and the cerebellar vermis.[9]

The origin of this condition is neurodevelopmental, with a prevalence of 3.4 to 7.2%, and it affects academic performance and social well-being.[10] Dopamine and norepinephrine reuptake inhibitors that maximize the availability of dopamine have proven to show excellent results.[11] Stimulants such as Methylphenidate (Ritalin), which are non-competitive reuptake inhibitors of dopamine and norepinephrine, block dopamine and norepinephrine transporters, substantially increasing their respective levels in the synaptic cleft.[12]

The nigrostriatal dopaminergic pathway connects the substantia nigra in the midbrain tegmentum to the striatum (caudate nucleus and putamen), controlling voluntary motor function, purposeful movement, and precise planning through the direct pathway, and inhibiting unwanted movement through the indirect pathway via GABAergic mechanisms. Parkinson's disease, the second most common neurodegenerative disease, which results when this pathway is compromised, is associated with a significant decrease in dopaminergic neurons, most notably in the striatum.[13] Evidence suggests a marked disruption in axonal dopamine release much before the eventual neurodegenerative lesion.[14]

Pharmacologic agents such as levodopa combined with Benserazide, a DOPA decarboxylase inhibitor which maximizes the therapeutic effects of dopamine in the brain, while agents such as Bromocriptine, a dopamine receptor agonist, offer symptomatic relief as well.[15] The downside of using antipsychotic medication, which blocks similar dopamine receptors, may produce extrapyramidal side effects such as pseudo-Parkinsonism, tardive dyskinesia, and acute dystonia.[5]

The tuberoinfundibular dopaminergic pathway is distinct from other dopaminergic pathways because of its neuroendocrine characterization. This links the hypothalamus to the pituitary gland through the prolactin-inhibiting hormone (dopamine) via the hypophysial portal tract, thereby inhibiting prolactin secretion from lactotrophs.[16] Atypical antipsychotics such as Risperidone, which exhibits a dose-dependent dopamine antagonistic activity, may lead to hyperprolactinemia. Galactorrhea, gynecomastia, menstrual irregularities, hypogonadism, and infertility may result because of the inhibition of GnRH release, accompanied by low levels of estrogen due to the elevated level of prolactin.[17] It is essential to note, however, that hypoprolactinemia may result when dopaminergic agonists such as Bromocriptine and Levodopa, typically used in the treatment of Parkinson's disease, are administered.[18]

CONCLUSION

It is critical to note that dopamine is an essential neurotransmitter with important regulatory effects both centrally and peripherally. The central effects contribute to a healthy, productive, highly regulated functional living when the levels are proportionate and optimally regulated. The manifestations resulting from dopamine imbalance in any of the closely related pathways, and the interconnected secondary consequences affecting other pathways, are significant and warrant adequate attention from health care professionals. A heightened level of awareness of these interactions by clinicians and health care professionals will provide a better understanding of intricate neurologic connections, the physiological implications, emerging pathological considerations, psychological dysfunctions, major side effects, and a rationale for implementing certain pharmacological interventions and definitive treatments.



Image generated by Copilot AI

REFERENCES

1. Drozak J, Bryła J. [Dopamine: not just a neurotransmitter]. Postępy Higieny I Medycyny Doświadczalnej (Online). 2005; 59:405-420.
2. Qianwei Liu, Tengteng Gao, Wenxuan Liu, Yusong Liu, Yongjuan Zhao, Yuerong Liu, et al. Functions of dopamine in plants: a review. Plant Signaling & Behavior. 2020;15(12):1827782.
3. Meiser J, Weindl D, Hiller K. Complexity of dopamine metabolism. Cell Commun Signal. 2013;11(1):34.
4. Bhatia A, Saadabadi A. Biochemistry, Dopamine Receptors. PubMed. Published June 22, 2023. Accessed July 14, 2026.
5. The Four Dopamine Pathways Relevant to Antipsychotic Pharmacology. Psychopharmacology Institute. Published March 13, 2023. https://psychopharmacologyinstitute.com/publication/the-four-dopamine-pathways-relevant-to-antipsychotics-pharmacology-2096/#references
6. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 1999;22(11):521-7.
7. Ruiz-Castañeda P, Santiago Molina E, Aguirre Loaiza H, Daza González MT. Positive symptoms of schizophrenia and their relationship with cognitive and emotional executive functions. Cogn Res Princ Implic . 2022;7(1):78.
8. Correll C, Schooler N. Negative Symptoms in schizophrenia: a Review and Clinical Guide for recognition, assessment, and Treatment. Neuropsychiatr Dis Treat. 2020;16:519–534.

9. Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. 2009;57(7-8):579-589.
10. Kessi M, Duan H, Xiong J, et al. Attention-deficit/hyperactivity disorder updates. ProQuest. 2022;15.
11. Biederman J. Attention-Deficit/Hyperactivity Disorder: A Selective Overview. Biol Psychiatry. 2005;57(11):1215-20.
12. Engert V, Pruessner JC. Dopaminergic and Noradrenergic Contributions to Functionality in ADHD: The Role of Methylphenidate. Curr Neuropharmacol. 2008;6(4):322-8.
13. Bourdy R, Sánchez-Catalán MJ, Kaufling J, et al. Control of the Nigrostriatal Dopamine Neuron Activity and Motor Function by the Tail of the Ventral Tegmental Area. Neuropsychopharmacology. 2014;39(12):2788-2798.
14. Cramb KML, Beccano-Kelly D, Cragg SJ, Wade-Martins R. Impaired dopamine release in Parkinson's disease. Brain. 2023;146(8).
15. Zahoor I, Shafi A, Haq E. Pharmacological Treatment of Parkinson's Disease. Parkinson's Disease: Pathogenesis and Clinical Aspects. 2018;Chapter 7(1):129-144.
16. Xiaojun Qi-Lytle, Sayers S, Wagner EJ. Current Review of the Function and Regulation of Tuberoinfundibular Dopamine Neurons. Int J Mol Sci. 2023;25(1):110.
17. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull. 2002 Winter;36(1):143-64.
18. Ioachimescu AG, Fahrettin Kelestimur. Drug-induced hypoprolactinemia. Rev Endocr Metab Disord . 2024;25(6):1003-1011.